Kendra Sweet, MD
Moffitt Cancer Center
Interview Date: June 9, 2022
Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. In this show, Dr. Kendra Sweet, an AML expert from Moffitt Cancer Center, shared with us about an antibody drug conjugate called IMGN632 and the current trials using this drug. IMGN632 targets CD123-positive AML cells and has shown promising results in relapsed/refractory patients in previous AML trials.
about the author
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Full Podcast Episode: Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic